Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High throughput discovery of new fouling-resistant surfaces.

Journal of materials chemistry·2017
Same author

Effects of solution conditions on virus retention by the Viresolve® NFP filter.

Biotechnology progress·2015
Same author

Probing effects of pressure release on virus capture during virus filtration using confocal microscopy.

Biotechnology and bioengineering·2015
Same author

Mechanistic evaluation of virus clearance by depth filtration.

Biotechnology progress·2015
Same author

A novel approach to achieving modular retrovirus clearance for a parvovirus filter.

Biotechnology progress·2013
Same author

Impact of virus preparation quality on parvovirus filter performance.

Biotechnology and bioengineering·2012
Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026
Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026
Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026
Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026
Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026
Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026
See all related articles

Related Experiment Videos

Tocilizumab.

Adith Venkiteshwaran1

  • 1Rensselaer Polytechnic Institute, Troy, NY, USA. sohini.mazumdar@tufts.edu

Mabs
|January 13, 2010
PubMed
Summary
This summary is machine-generated.

Tocilizumab, an anti-interleukin-6 receptor antibody, is being developed for rheumatoid arthritis and other IL-6 related conditions. It is already approved for arthritis in the EU and marketed in Japan for Castleman disease.

Related Experiment Videos

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor (IL-6R).
  • It is developed by Roche and Chugai Pharmaceutical.
  • Current applications include Castleman disease and arthritis in Japan.

Purpose of the Study:

  • To evaluate tocilizumab for moderate-to-severe rheumatoid arthritis.
  • To explore its potential in other IL-6 related disorders, such as Crohn disease.

Main Methods:

  • Clinical development and regulatory review processes.
  • Investigational studies for various IL-6 mediated conditions.

Main Results:

  • Tocilizumab is approved in the EU for moderate-to-severe rheumatoid arthritis.
  • It is under review by the US FDA for rheumatoid arthritis.
  • Marketed in Japan for Castleman disease and several types of arthritis.

Conclusions:

  • Tocilizumab demonstrates efficacy in treating rheumatoid arthritis and Castleman disease.
  • Further research is exploring its utility in other inflammatory conditions like Crohn disease.